Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 34 entries
Sorted by: Best Match Show Resources per page
Letter to the Editor on: "Population Pharmacokinetics of Dalbavancin and Dosing Considerations for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections".

Antimicrobial agents and chemotherapy

Baklouti S, Marolleau S, Chavanet P, Bonnet E, Concordet, Gandia P.
PMID: 34662193
Antimicrob Agents Chemother. 2021 Oct 18;AAC0149321. doi: 10.1128/AAC.01493-21. Epub 2021 Oct 18.

Dear Editor, Recently, Cojutti et al. [1] published a population pharmacokinetic (POP PK) model on dalbavancin administered to adult patients with Staphylococcal osteoarticular infections (OAI).….

Cite
Baklouti S, Marolleau S, Chavanet P, et al. Letter to the Editor on: "Population Pharmacokinetics of Dalbavancin and Dosing Considerations for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections". Antimicrob Agents Chemother. 2021;AAC0149321doi: 10.1128/AAC.01493-21.
Baklouti, S., Marolleau, S., Chavanet, P., Bonnet, E., Concordet, & Gandia, P. (2021). Letter to the Editor on: "Population Pharmacokinetics of Dalbavancin and Dosing Considerations for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections". Antimicrobial agents and chemotherapy, AAC0149321. https://doi.org/10.1128/AAC.01493-21
Baklouti, S, et al. "Letter to the Editor on: "Population Pharmacokinetics of Dalbavancin and Dosing Considerations for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections"." Antimicrobial agents and chemotherapy vol. (2021): AAC0149321. doi: https://doi.org/10.1128/AAC.01493-21
Baklouti S, Marolleau S, Chavanet P, Bonnet E, Concordet, Gandia P. Letter to the Editor on: "Population Pharmacokinetics of Dalbavancin and Dosing Considerations for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections". Antimicrob Agents Chemother. 2021 Oct 18;AAC0149321. doi: 10.1128/AAC.01493-21. Epub 2021 Oct 18. PMID: 34662193.
Copy Download .nbib Format: NLM
Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods.

Leukemia

Corre J, Perrot A, Hulin C, Caillot D, Stoppa AM, Facon T, Leleu X, Dib M, Karlin L, Moreau P, Mohty M, Mariette C, Fontan J, Marolleau JP, Demarquette H, Slama B, Voillat L, Macro M, Orsini-Piocelle F, Brechignac S, Rey P, Collet P, Tiab M, Belhadj K, Lifermann F, Clement-Filliatre L, Sohn C, Richez V, Avet-Loiseau H.
PMID: 34099876
Leukemia. 2021 Dec;35(12):3600-3603. doi: 10.1038/s41375-021-01250-0. Epub 2021 Jun 07.

No abstract available.

Cite
Corre J, Perrot A, Hulin C, et al. Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. Leukemia. 2021;35(12):3600-3603doi: 10.1038/s41375-021-01250-0.
Corre, J., Perrot, A., Hulin, C., Caillot, D., Stoppa, A. M., Facon, T., Leleu, X., Dib, M., Karlin, L., Moreau, P., Mohty, M., Mariette, C., Fontan, J., Marolleau, J. P., Demarquette, H., Slama, B., Voillat, L., Macro, M., Orsini-Piocelle, F., Brechignac, S., Rey, P., Collet, P., Tiab, M., Belhadj, K., Lifermann, F., Clement-Filliatre, L., Sohn, C., Richez, V., Avet-Loiseau, H. (2021). Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. Leukemia, 35(12), 3600-3603. https://doi.org/10.1038/s41375-021-01250-0
Corre, Jill, et al. "Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods." Leukemia vol. 35,12 (2021): 3600-3603. doi: https://doi.org/10.1038/s41375-021-01250-0
Corre J, Perrot A, Hulin C, Caillot D, Stoppa AM, Facon T, Leleu X, Dib M, Karlin L, Moreau P, Mohty M, Mariette C, Fontan J, Marolleau JP, Demarquette H, Slama B, Voillat L, Macro M, Orsini-Piocelle F, Brechignac S, Rey P, Collet P, Tiab M, Belhadj K, Lifermann F, Clement-Filliatre L, Sohn C, Richez V, Avet-Loiseau H. Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. Leukemia. 2021 Dec;35(12):3600-3603. doi: 10.1038/s41375-021-01250-0. Epub 2021 Jun 07. PMID: 34099876.
Copy Download .nbib Format: NLM
Short-lived recombinant adeno-associated virus transgene expression in dystrophic muscle is associated with oxidative damage to transgene mRNA.

Molecular therapy. Methods & clinical development

Dupont JB, Tournaire B, Georger C, Marolleau B, Jeanson-Leh L, Ledevin M, Lindenbaum P, Lecomte E, Cogné B, Dubreil L, Larcher T, Gjata B, Van Wittenberghe L, Le Guiner C, Penaud-Budloo M, Snyder RO, Moullier P, Léger A.
PMID: 26029721
Mol Ther Methods Clin Dev. 2015 Apr 08;2:15010. doi: 10.1038/mtm.2015.10. eCollection 2015.

Preclinical gene therapy strategies using recombinant adeno-associated virus (AAV) vectors in animal models of Duchenne muscular dystrophy have shown dramatic phenotype improvements, but long-lasting efficacy remains questionable. It is believed that in dystrophic muscles, transgene persistence is hampered, notably...

Cite
Dupont JB, Tournaire B, Georger C, et al. Short-lived recombinant adeno-associated virus transgene expression in dystrophic muscle is associated with oxidative damage to transgene mRNA. Mol Ther Methods Clin Dev. 2015;2:15010doi: 10.1038/mtm.2015.10.
Dupont, J. B., Tournaire, B., Georger, C., Marolleau, B., Jeanson-Leh, L., Ledevin, M., Lindenbaum, P., Lecomte, E., Cogné, B., Dubreil, L., Larcher, T., Gjata, B., Van Wittenberghe, L., Le Guiner, C., Penaud-Budloo, M., Snyder, R. O., Moullier, P., & Léger, A. (2015). Short-lived recombinant adeno-associated virus transgene expression in dystrophic muscle is associated with oxidative damage to transgene mRNA. Molecular therapy. Methods & clinical development, 215010. https://doi.org/10.1038/mtm.2015.10
Dupont, Jean-Baptiste, et al. "Short-lived recombinant adeno-associated virus transgene expression in dystrophic muscle is associated with oxidative damage to transgene mRNA." Molecular therapy. Methods & clinical development vol. 2 (2015): 15010. doi: https://doi.org/10.1038/mtm.2015.10
Dupont JB, Tournaire B, Georger C, Marolleau B, Jeanson-Leh L, Ledevin M, Lindenbaum P, Lecomte E, Cogné B, Dubreil L, Larcher T, Gjata B, Van Wittenberghe L, Le Guiner C, Penaud-Budloo M, Snyder RO, Moullier P, Léger A. Short-lived recombinant adeno-associated virus transgene expression in dystrophic muscle is associated with oxidative damage to transgene mRNA. Mol Ther Methods Clin Dev. 2015 Apr 08;2:15010. doi: 10.1038/mtm.2015.10. eCollection 2015. PMID: 26029721; PMCID: PMC4445007.
Copy Download .nbib Format: NLM
Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16.

Journal of contemporary brachytherapy

Schoentgen N, Marolleau J, Delage F, Coquet JB, Fourcade A, Callerot P, Serey-Eiffel S, Malhaire JP, Pradier O, Schick U, Fournier G, Valeri A.
PMID: 31435425
J Contemp Brachytherapy. 2019 Jun;11(3):195-200. doi: 10.5114/jcb.2019.85793. Epub 2019 Jun 28.

PURPOSE: Prostate brachytherapy (BT) is a validated treatment for localized prostate cancer (CaP) and an attractive therapy option for patients seeking to preserve erectile function (EF). The aim of this paper is to prospectively assess EF evolution during 4...

Cite
Schoentgen N, Marolleau J, Delage F, et al. Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16. J Contemp Brachytherapy. 2019;11(3):195-200doi: 10.5114/jcb.2019.85793.
Schoentgen, N., Marolleau, J., Delage, F., Coquet, J. B., Fourcade, A., Callerot, P., Serey-Eiffel, S., Malhaire, J. P., Pradier, O., Schick, U., Fournier, G., & Valeri, A. (2019). Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16. Journal of contemporary brachytherapy, 11(3), 195-200. https://doi.org/10.5114/jcb.2019.85793
Schoentgen, Nadja, et al. "Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16." Journal of contemporary brachytherapy vol. 11,3 (2019): 195-200. doi: https://doi.org/10.5114/jcb.2019.85793
Schoentgen N, Marolleau J, Delage F, Coquet JB, Fourcade A, Callerot P, Serey-Eiffel S, Malhaire JP, Pradier O, Schick U, Fournier G, Valeri A. Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16. J Contemp Brachytherapy. 2019 Jun;11(3):195-200. doi: 10.5114/jcb.2019.85793. Epub 2019 Jun 28. PMID: 31435425; PMCID: PMC6701385.
Copy Download .nbib Format: NLM
Epstein-Barr Virus-related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti-CD30.

Clinical case reports

Montes L, Tredez E, Yzet C, Delette C, Chatelain D, Lebon D, Fumery M, Marolleau JP.
PMID: 32577242
Clin Case Rep. 2020 Apr 08;8(6):958-961. doi: 10.1002/ccr3.2721. eCollection 2020 Jun.

Epstein-Barr virus-related mucocutaneous ulcer lymphoma is a rare entity promoted by immunosuppression. It is less described in inflammatory bowel diseases, and mostly these are refractory diseases. CD30 acts to Epstein-Barr virus (EBV) local proliferation and thus could be an...

Cite
Montes L, Tredez E, Yzet C, et al. Epstein-Barr Virus-related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti-CD30. Clin Case Rep. 2020;8(6):958-961doi: 10.1002/ccr3.2721.
Montes, L., Tredez, E., Yzet, C., Delette, C., Chatelain, D., Lebon, D., Fumery, M., & Marolleau, J. P. (2020). Epstein-Barr Virus-related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti-CD30. Clinical case reports, 8(6), 958-961. https://doi.org/10.1002/ccr3.2721
Montes, Lydia, et al. "Epstein-Barr Virus-related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti-CD30." Clinical case reports vol. 8,6 (2020): 958-961. doi: https://doi.org/10.1002/ccr3.2721
Montes L, Tredez E, Yzet C, Delette C, Chatelain D, Lebon D, Fumery M, Marolleau JP. Epstein-Barr Virus-related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti-CD30. Clin Case Rep. 2020 Apr 08;8(6):958-961. doi: 10.1002/ccr3.2721. eCollection 2020 Jun. PMID: 32577242; PMCID: PMC7303872.
Copy Download .nbib Format: NLM
The Warburg Effect as a Type B Lactic Acidosis in a Patient With Acute Myeloid Leukemia: A Diagnostic Challenge for Clinicians.

Frontiers in oncology

Brault C, Zerbib Y, Delette C, Marc J, Gruson B, Marolleau JP, Maizel J.
PMID: 29974036
Front Oncol. 2018 Jun 20;8:232. doi: 10.3389/fonc.2018.00232. eCollection 2018.

INTRODUCTION: The Warburg effect (WE) is an uncommon cause of type B lactic acidosis (LA) due to a deregulation of carbohydrate metabolism in neoplastic cells where lactic fermentation predominates over oxidative phosphorylation regardless of the oxygen level.CASE PRESENTATION: We...

Cite
Brault C, Zerbib Y, Delette C, et al. The Warburg Effect as a Type B Lactic Acidosis in a Patient With Acute Myeloid Leukemia: A Diagnostic Challenge for Clinicians. Front Oncol. 2018;8:232doi: 10.3389/fonc.2018.00232.
Brault, C., Zerbib, Y., Delette, C., Marc, J., Gruson, B., Marolleau, J. P., & Maizel, J. (2018). The Warburg Effect as a Type B Lactic Acidosis in a Patient With Acute Myeloid Leukemia: A Diagnostic Challenge for Clinicians. Frontiers in oncology, 8232. https://doi.org/10.3389/fonc.2018.00232
Brault, Clément, et al. "The Warburg Effect as a Type B Lactic Acidosis in a Patient With Acute Myeloid Leukemia: A Diagnostic Challenge for Clinicians." Frontiers in oncology vol. 8 (2018): 232. doi: https://doi.org/10.3389/fonc.2018.00232
Brault C, Zerbib Y, Delette C, Marc J, Gruson B, Marolleau JP, Maizel J. The Warburg Effect as a Type B Lactic Acidosis in a Patient With Acute Myeloid Leukemia: A Diagnostic Challenge for Clinicians. Front Oncol. 2018 Jun 20;8:232. doi: 10.3389/fonc.2018.00232. eCollection 2018. PMID: 29974036; PMCID: PMC6019439.
Copy Download .nbib Format: NLM
Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?.

Antimicrobial agents and chemotherapy

Baklouti S, Marolleau S, Chavanet P, Bonnet E, Concordet D, Gandia P.
PMID: 34662193
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0149321. doi: 10.1128/AAC.01493-21. Epub 2021 Oct 18.

No abstract available.

Cite
Baklouti S, Marolleau S, Chavanet P, et al. Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?. Antimicrob Agents Chemother. 2021;66(1):e0149321doi: 10.1128/AAC.01493-21.
Baklouti, S., Marolleau, S., Chavanet, P., Bonnet, E., Concordet, D., & Gandia, P. (2022). Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?. Antimicrobial agents and chemotherapy, 66(1), e0149321. https://doi.org/10.1128/AAC.01493-21
Baklouti, S, et al. "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?." Antimicrobial agents and chemotherapy vol. 66,1 (2022): e0149321. doi: https://doi.org/10.1128/AAC.01493-21
Baklouti S, Marolleau S, Chavanet P, Bonnet E, Concordet D, Gandia P. Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0149321. doi: 10.1128/AAC.01493-21. Epub 2021 Oct 18. PMID: 34662193.
Copy Download .nbib Format: NLM
Is Hematopoietic Clonality of Indetermined Potential a Risk Factor for Pulmonary Embolism?.

TH open : companion journal to thrombosis and haemostasis

Soudet S, Jedraszak G, Evrard O, Marolleau JP, Garcon L, Pietri MAS.
PMID: 34414354
TH Open. 2021 Aug 17;5(3):e338-e342. doi: 10.1055/s-0041-1733856. eCollection 2021 Jul.

No abstract available.

Cite
Soudet S, Jedraszak G, Evrard O, et al. Is Hematopoietic Clonality of Indetermined Potential a Risk Factor for Pulmonary Embolism?. TH Open. 2021;5(3):e338-e342doi: 10.1055/s-0041-1733856.
Soudet, S., Jedraszak, G., Evrard, O., Marolleau, J. P., Garcon, L., & Pietri, M. A. S. (2021). Is Hematopoietic Clonality of Indetermined Potential a Risk Factor for Pulmonary Embolism?. TH open : companion journal to thrombosis and haemostasis, 5(3), e338-e342. https://doi.org/10.1055/s-0041-1733856
Soudet, S, et al. "Is Hematopoietic Clonality of Indetermined Potential a Risk Factor for Pulmonary Embolism?." TH open : companion journal to thrombosis and haemostasis vol. 5,3 (2021): e338-e342. doi: https://doi.org/10.1055/s-0041-1733856
Soudet S, Jedraszak G, Evrard O, Marolleau JP, Garcon L, Pietri MAS. Is Hematopoietic Clonality of Indetermined Potential a Risk Factor for Pulmonary Embolism?. TH Open. 2021 Aug 17;5(3):e338-e342. doi: 10.1055/s-0041-1733856. eCollection 2021 Jul. PMID: 34414354; PMCID: PMC8370792.
Copy Download .nbib Format: NLM
When a Plant Resistance Inducer Leaves the Lab for the Field: Integrating ASM into Routine Apple Protection Practices.

Frontiers in plant science

Marolleau B, Gaucher M, Heintz C, Degrave A, Warneys R, Orain G, Lemarquand A, Brisset MN.
PMID: 29255473
Front Plant Sci. 2017 Dec 04;8:1938. doi: 10.3389/fpls.2017.01938. eCollection 2017.

Plant resistance inducers, also called elicitors, could be useful to reduce the use of pesticides. However, their performance in controlling diseases in the field remains unsatisfactory due to lack of specific knowledge of how they can integrate crop protection...

Cite
Marolleau B, Gaucher M, Heintz C, et al. When a Plant Resistance Inducer Leaves the Lab for the Field: Integrating ASM into Routine Apple Protection Practices. Front Plant Sci. 2017;8:1938doi: 10.3389/fpls.2017.01938.
Marolleau, B., Gaucher, M., Heintz, C., Degrave, A., Warneys, R., Orain, G., Lemarquand, A., & Brisset, M. N. (2017). When a Plant Resistance Inducer Leaves the Lab for the Field: Integrating ASM into Routine Apple Protection Practices. Frontiers in plant science, 81938. https://doi.org/10.3389/fpls.2017.01938
Marolleau, Brice, et al. "When a Plant Resistance Inducer Leaves the Lab for the Field: Integrating ASM into Routine Apple Protection Practices." Frontiers in plant science vol. 8 (2017): 1938. doi: https://doi.org/10.3389/fpls.2017.01938
Marolleau B, Gaucher M, Heintz C, Degrave A, Warneys R, Orain G, Lemarquand A, Brisset MN. When a Plant Resistance Inducer Leaves the Lab for the Field: Integrating ASM into Routine Apple Protection Practices. Front Plant Sci. 2017 Dec 04;8:1938. doi: 10.3389/fpls.2017.01938. eCollection 2017. PMID: 29255473; PMCID: PMC5723009.
Copy Download .nbib Format: NLM
Myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review.

Advances in hematology

Etienne A, Gruson B, Chatelain D, Garidi R, Royer B, Sevestre H, Marolleau JP, Damaj G.
PMID: 20049166
Adv Hematol. 2009;2009:179847. doi: 10.1155/2009/179847. Epub 2009 Nov 25.

Background. To better describe the clinical, biological, and the outcome of non-Hodgkin's lymphoma (NHL) with, at the initial presentation, bone marrow fibrosis (MF). Patients and Methods. From January 2001 to January 2007, 16 eligible patients with NHL and MF...

Cite
Etienne A, Gruson B, Chatelain D, et al. Myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review. Adv Hematol. 2009;2009:179847doi: 10.1155/2009/179847.
Etienne, A., Gruson, B., Chatelain, D., Garidi, R., Royer, B., Sevestre, H., Marolleau, J. P., & Damaj, G. (2009). Myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review. Advances in hematology, 2009179847. https://doi.org/10.1155/2009/179847
Etienne, A, et al. "Myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review." Advances in hematology vol. 2009 (2009): 179847. doi: https://doi.org/10.1155/2009/179847
Etienne A, Gruson B, Chatelain D, Garidi R, Royer B, Sevestre H, Marolleau JP, Damaj G. Myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review. Adv Hematol. 2009;2009:179847. doi: 10.1155/2009/179847. Epub 2009 Nov 25. PMID: 20049166; PMCID: PMC2798566.
Copy Download .nbib Format: NLM
TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells.

Frontiers in immunology

Ghamlouch H, Ouled-Haddou H, Guyart A, Regnier A, Trudel S, Claisse JF, Fuentes V, Royer B, Marolleau JP, Gubler B.
PMID: 24982661
Front Immunol. 2014 Jun 16;5:292. doi: 10.3389/fimmu.2014.00292. eCollection 2014.

B-cell chronic lymphocytic leukemia (CLL) is the most frequent adult leukemia in the Western world. It is a heterogeneous disease characterized by clonal proliferation and the accumulation of CD5(+) mature B lymphocytes. However, the normal counterpart from which the...

Cite
Ghamlouch H, Ouled-Haddou H, Guyart A, et al. TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells. Front Immunol. 2014;5:292doi: 10.3389/fimmu.2014.00292.
Ghamlouch, H., Ouled-Haddou, H., Guyart, A., Regnier, A., Trudel, S., Claisse, J. F., Fuentes, V., Royer, B., Marolleau, J. P., & Gubler, B. (2014). TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells. Frontiers in immunology, 5292. https://doi.org/10.3389/fimmu.2014.00292
Ghamlouch, Hussein, et al. "TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells." Frontiers in immunology vol. 5 (2014): 292. doi: https://doi.org/10.3389/fimmu.2014.00292
Ghamlouch H, Ouled-Haddou H, Guyart A, Regnier A, Trudel S, Claisse JF, Fuentes V, Royer B, Marolleau JP, Gubler B. TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells. Front Immunol. 2014 Jun 16;5:292. doi: 10.3389/fimmu.2014.00292. eCollection 2014. PMID: 24982661; PMCID: PMC4058906.
Copy Download .nbib Format: NLM
The first use of laparoscopy to treat pelvic ring fractures: A case report.

International journal of surgery case reports

Di Francia R, Tanner JL, Marolleau J.
PMID: 33011656
Int J Surg Case Rep. 2020;76:60-63. doi: 10.1016/j.ijscr.2020.09.162. Epub 2020 Sep 25.

INTRODUCTION: Pelvic ring injuries pose major challenges for the trauma surgeon. Given the complications of open surgeries, percutaneous techniques have become increasingly popular, but laparoscopy has never been employed for internal osteosynthesis of the pelvic ring.PRESENTATION OF CASE: We...

Cite
Di Francia R, Tanner JL, Marolleau J. The first use of laparoscopy to treat pelvic ring fractures: A case report. Int J Surg Case Rep. 2020;76:60-63doi: 10.1016/j.ijscr.2020.09.162.
Di Francia, R., Tanner, J. L., & Marolleau, J. (2020). The first use of laparoscopy to treat pelvic ring fractures: A case report. International journal of surgery case reports, 7660-63. https://doi.org/10.1016/j.ijscr.2020.09.162
Di Francia, Rémi, et al. "The first use of laparoscopy to treat pelvic ring fractures: A case report." International journal of surgery case reports vol. 76 (2020): 60-63. doi: https://doi.org/10.1016/j.ijscr.2020.09.162
Di Francia R, Tanner JL, Marolleau J. The first use of laparoscopy to treat pelvic ring fractures: A case report. Int J Surg Case Rep. 2020;76:60-63. doi: 10.1016/j.ijscr.2020.09.162. Epub 2020 Sep 25. PMID: 33011656; PMCID: PMC7530218.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 34 entries